Supreme Court of the United States · Official docket →

Nuvo Pharmaceuticals (Ireland) Designated Activity Company, et al. v. Dr. Reddy's Laboratories Inc., et al.

Paid petition · United States Court of Appeals for the Federal Circuit, No. 2017-2473, 2017-2481, 2017-2484, 2017-2486, 2017-2489, 2017-2491, 2017-2492, 2017-2493 · judgment May 15, 2019

Certiorari denied · January 13, 2020

Pre-decision estimate: 2% cert probability

Before the decision, well below the 4.1% base rate, with no standout signals pointing toward a grant.

Question presented

Whether the Federal Circuit erred by holding that, whenever the prior art teaches away from a pharmaceutical composition, the written description of a patent claiming that composition can satisfy 35 U.S.C. § 112 only if it discloses either experimental data proving efficacy or a detailed theory of why the composition works sufficient to show that it would be effective.

Counsel of record

For petitioner
James Burton Monroe
Finnegan, Henderson, Farabow, et. al.

For respondent
Dan L. Bagatell
Perkins Coie LLP

Case

Conference history
Distributed for 1 conference

Proceedings

Jan 13 2020
Petition DENIED.
Dec 11 2019
DISTRIBUTED for Conference of 1/10/2020.
Dec 04 2019
Waiver of right of respondents Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories, Ltd. to respond filed.
Dec 04 2019
Waiver of right of respondents Mylan Inc., Mylan Pharmaceuticals Inc., Mylan Laboratories Limited to respond filed.
Oct 28 2019
Petition for a writ of certiorari filed. (Response due December 4, 2019)